Capstone Investment Advisors, LLC Gilead Sciences, Inc. Put Options Transaction History

Capstone Investment Advisors, LLC

$24.9 Billion
Q1 2024

Put Options

26 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 01, 2024	SELL	$71.58 - $87.29 $5.28 Million - $6.44 Million	-73,800 Reduced 36.61%	127,800 $9.36 Million
Q4 2023 Feb 12, 2024	BUY	$73.27 - $83.09 $5.72 Million - $6.48 Million	78,000 Added 63.11%	201,600 $16.3 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $2.26 Million - $2.46 Million	30,500 Added 32.76%	123,600 $9.26 Million
Q2 2023 Aug 10, 2023	BUY	$76.01 - $86.7 $2.49 Million - $2.84 Million	32,700 Added 54.14%	93,100 $7.18 Million
Q1 2023 May 09, 2023	SELL	$77.31 - $88.08 $15.5 Million - $17.7 Million	-200,400 Reduced 76.84%	60,400 $5.01 Million

Q4 2022 Feb 10, 2023	BUY	$62.32 - $89.47 $386,384 - $554,714	6,200 Added 2.44%	260,800 $22.4 Million
Q3 2022 Nov 10, 2022	BUY	$59.54 - $68.01 $660,894 - $754,911	11,100 Added 4.56%	254,600 $15.7 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $19.3 Million - $21.7 Million	-333,800 Reduced 57.82%	243,500 $15.1 Million
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $40 Million - $50.2 Million	-691,300 Reduced 54.49%	577,300 $34.3 Million
Q4 2021 Feb 11, 2022	SELL	$64.88 - $73.64 $3.1 Million - $3.52 Million	-47,800 Reduced 3.63%	1,268,600 $92.1 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $12.4 Million - $13.4 Million	183,400 Added 16.19%	1,316,400 $92 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $16.4 Million - $17.9 Million	258,500 Added 29.56%	1,133,000 $78 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $19.5 Million - $22.3 Million	325,700 Added 59.35%	874,500 $56.5 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $6.31 Million - $7.18 Million	-111,300 Reduced 16.86%	548,800 $32 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $9 Million - $11.3 Million	145,000 Added 28.15%	660,100 $41.7 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $29.1 Million - $33.8 Million	402,700 Added 358.27%	515,100 $39.6 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $21.8 Million - $28 Million	-348,600 Reduced 75.62%	112,400 $8.4 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $6.5 Million - $7.15 Million	105,500 Added 29.68%	461,000 $30 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $3.99 Million - $4.4 Million	63,800 Added 21.87%	355,500 $22.5 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $4.9 Million - $5.49 Million	79,200 Added 37.27%	291,700 $19.7 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $4.49 Million - $5.03 Million	71,800 Added 51.03%	212,500 $13.8 Million
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $2.2 Million - $2.88 Million	36,400 Added 34.9%	140,700 $8.8 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $3.69 Million - $4.08 Million	51,700 Added 98.29%	104,300 $8.05 Million
Q2 2018 Aug 13, 2018	BUY	$64.88 - $75.68 $3.19 Million - $3.72 Million	49,100 Added 1402.86%	52,600 $3.73 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $101,976 - $124,320	1,400 Added 66.67%	3,500 $264,000
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $151,431 - $179,487	2,100	2,100 $170,000

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

Black Rock Inc. New York, NY

123M
Shares

$8.38 Billion
0.21% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$7.85 Billion
0.17% of portfolio
Capital World Investors Los Angeles, CA

84.5M
Shares

$5.78 Billion
1.06% of portfolio
Capital Research Global Investors Los Angeles, CA

61.2M
Shares

$4.19 Billion
1.05% of portfolio
State Street Corp Boston, MA

57.7M
Shares

$3.95 Billion
0.19% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.

Account